Drug Trial Radar · NCT02820324
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
Last checked: Nov 20, 2026Latest source record: Oct 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
407
Actual
Start
May 2016
Primary completion
Dec 2016
Study completion Jan 2017
Sponsor
- Lead sponsor
- Trevena Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 30, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the analgesic efficacy of intravenous (IV) oliceridine administered as needed (PRN) compared with placebo in patients with moderate to severe acute pain after abdominoplasty.
Conditions
- Acute Pain
Interventions
OliceridineDrug
PlaceboDrug
MorphineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Who Respond to Study Medication at the 24-hr Numeric Pain Rating Scale (NPRS) Assessment Compared to Placebo.Time frame: 24 hours
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Pasadena, California
Research Site
Pasadena, Maryland
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.